Fosamax and Osteonecrosis of the Jaw: Scientific Evidence of Causation
Latest update (2026-05)
FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]
Legacy Context and Evolving Understanding
The legacy context of general health and science information has long provided a foundation for understanding broad physiological principles and the importance of evidence-based inquiry. Within this framework, public health communications have historically emphasized the balance between therapeutic benefits and potential adverse effects of medical interventions. This heritage includes the careful dissemination of findings related to pharmaceutical safety, where initial reports of rare complications gradually accumulate into recognized risk profiles. One such area of evolving understanding involves the relationship between bisphosphonate therapy, specifically Fosamax, and the development of osteonecrosis of the jaw. Originally observed in oncology patients receiving high-dose intravenous bisphosphonates, this condition later emerged in the context of oral formulations used for osteoporosis management. The scientific discourse has since focused on establishing causation, examining biological plausibility, and identifying patient-specific risk factors.
From General Health to Occupational Exposure
As this knowledge base matures, it becomes increasingly relevant to consider how such pharmaceutical exposures translate into occupational settings. The transition from general health awareness to occupational exposure concern is marked by the recognition that healthcare professionals, dental practitioners, and others who handle or administer these compounds may face distinct risk considerations. This pivot requires a shift from population-level risk communication to workplace-specific hazard assessment, where the focus narrows to exposure routes, duration, and cumulative effects relevant to professional environments. Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism involves inhibiting bone resorption, which increases bone mass and reduces fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).
Clinical Evidence Linking Fosamax to Osteonecrosis of the Jaw
A serious adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. It can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Clinical presentation often involves pain, swelling, and exposed bone that fails to heal after dental procedures. Diagnosis is based on clinical examination and imaging, with a key feature being the presence of necrotic bone in the jaw that persists for more than eight weeks in the absence of radiation therapy. The scientific evidence connecting Fosamax to ONJ is supported by multiple lines of investigation. First, clinical reports have documented ONJ in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, and a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This pattern supports a causal relationship, as the condition appears to be temporally associated with drug exposure and can be reproduced upon re-exposure.
Mechanistic Pathways and Risk Factors
Mechanistic pathways linking Fosamax to ONJ involve the drug's potent inhibition of osteoclast activity. Bisphosphonates like alendronate accumulate in bone, particularly in areas of high turnover such as the jaw. This accumulation can suppress bone remodeling, leading to impaired healing after dental procedures or microtrauma. The jawbone's unique structure and function may make it particularly susceptible to bisphosphonate-related complications. A multiscale characterization of jawbone treated with osteoporosis therapeutic agents in estrogen-deficient rats found that bisphosphonate treatment affected the jawbone's mechanical stability and tissue mineral density distribution (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research provides comprehensive information that can help understand jawbone-specific responses to bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). The study suggests that bisphosphonates alter the jawbone's material properties, potentially increasing vulnerability to necrosis. Risk factors for developing ONJ while taking Fosamax include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).
Adequacy of Warnings and Causation Considerations
Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This warning describes the condition, its association with dental procedures, and the potential for increased risk with longer exposure. However, in placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that ONJ is a rare event that may not be fully captured in clinical trials, and the warning serves to alert clinicians to this potential risk. For affected patients, causation-related considerations include the timeline between exposure and documented harm. The onset of ONJ symptoms can occur from one day to several months after starting Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This variable latency complicates establishing a direct causal link in individual cases, as other factors such as dental procedures or infections may also contribute. Nevertheless, the recurrence of symptoms upon rechallenge with bisphosphonates provides strong evidence of a drug-related effect (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Patients who develop ONJ should discontinue Fosamax and receive appropriate dental care.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the scientific evidence connecting Fosamax to osteonecrosis of the jaw?
What are the risk factors for developing osteonecrosis of the jaw while taking Fosamax?
Risk factors include invasive dental procedures, cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures, and longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).
How is osteonecrosis of the jaw diagnosed?
Diagnosis is based on clinical examination and imaging, with a key feature being the presence of necrotic bone in the jaw that persists for more than eight weeks in the absence of radiation therapy.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.